MSB-CAR001 Combined With Hyaluronan + Hyaluronan
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anterior Cruciate Ligament Injury
Conditions
Anterior Cruciate Ligament Injury, Osteoarthritis
Trial Timeline
Mar 1, 2009 → Oct 1, 2014
NCT ID
NCT01088191About MSB-CAR001 Combined With Hyaluronan + Hyaluronan
MSB-CAR001 Combined With Hyaluronan + Hyaluronan is a phase 1/2 stage product being developed by Mesoblast for Anterior Cruciate Ligament Injury. The current trial status is completed. This product is registered under clinical trial identifier NCT01088191. Target conditions include Anterior Cruciate Ligament Injury, Osteoarthritis.
Hype Score Breakdown
Clinical
13
Activity
8
Company
5
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01088191 | Phase 1/2 | Completed |
Competing Products
9 competing products in Anterior Cruciate Ligament Injury
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| PDE5 Inhibitors | Eli Lilly | Pre-clinical | 23 |
| Rosuvastatin | AstraZeneca | Approved | 85 |
| Diagnostic procedures | Bayer | Approved | 82 |
| Topical Prednisolone Acetate 1% | Ocular Therapeutix | Approved | 80 |
| OMS103HP + Vehicle | Omeros Corporation | Phase 3 | 72 |
| Valganciclovir Hydrochloride + Ganciclovir Sodium + Placebo Oral Tablet + Topical placebo | Pacific Biosciences | Phase 2/3 | 57 |
| Abciximab local infusion | Atrium Therapeutics | Pre-clinical | 15 |
| ADX-102 Ophthalmic Solution (0.5%) + Vehicle of ADX-102 Ophthalmic Solution | Aldeyra Therapeutics | Phase 3 | 69 |
| NS2 + Prednisolone acetate ophthalmic suspension (1%) | Aldeyra Therapeutics | Phase 2 | 44 |